BioLineRx Ltd. (BLRX) today announced it received a Notice of Allowance of US patent for its Celiac disease candidate drug, BL-7010.
In a report released this morning, Roth Capital analyst Joseph Pantginis reinitiated coverage on BioLineRx Ltd. (BLRX) with a Buy rating and an $8.
